靶向 CD19、CD20 和 CD22 的床旁制备三特异性 CAR-T 细胞首次人体试验的安全性与临床结局

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

复发/难治性大 B 细胞淋巴瘤中基线免疫细胞组成与 CAR-T 细胞扩增及生存的关联

Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.

基线免疫细胞组成可能与 R/R 大 B 细胞淋巴瘤中 CAR-T 的扩增和结局相关。

DLBCL 活体供者接受 CD19/CD22 CAR-T 细胞鸡尾酒疗法后长期完全缓解及轻微副作用：一例罕见病例报告

Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.

ASCT 后序贯 CD19/CD22 CAR-T 细胞治疗在复发/难治性大 B 细胞淋巴瘤中较单纯 CAR-T 显示出更优疗效

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma.

双特异性抗体治疗失败后复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞挽救治疗的疗效与安全性分析

Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody t

CAR-T 挽救治疗在 BsAb R/R DLBCL 患者中显示出高缓解率和可控的安全性。早期生存数据表明，在这一 BsAb 耐药的高危人群中具有令人鼓舞的临床获益，尽管需要延长随访以确认持久性。本研究为 CAR-T 作为该情境下的一种潜在挽救策略提供了支持性证据。

CD22 特异性 T 细胞受体实现 B 细胞恶性肿瘤的有效过继 T 细胞治疗

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.

免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征的临床与细胞因子特征

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

2026 年白血病的照护与治愈

The Care and Cure of the Leukemias in 2026.

在靶点选择指导下，inotuzumab ozogamicin 成功挽救一例抗 CD19 和抗 CD22 CAR-T 细胞治疗后的难治性滤泡性淋巴瘤患者：病例报告与文献综述

Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CA